U.S Market Study on Polycystic Ovarian Syndrome Treatment

Mar 2017| PMR191A| Persistence Market Research

Report Highlights

The polycystic ovarian syndrome treatment market in the U.S is highly competitive due to the presence of many local manufacturers and prevalence of low-cost generic drugs. However, manufacturers of brands in the country have strategically maintained their position in the market, owing to the unique value proposition and comparatively lesser side effects. The analysts of Persistence Market Research, while drafting a report on the U.S. polycystic ovarian syndrome treatment market titled “Polycystic Ovarian Syndrome Treatment Market: U.S. Industry Analysis and Forecast, 2016–2024,” have observed that alliances with e-commerce partners and distribution agreements with strong local players is the key market strategy that is being followed by leading players in this market. While concentrating on target geographies, the analysts have further observed that the U.S. is a highly mature market where manufacturers are focused on developing advanced direct first line therapeutics for the treatment of polycystic ovarian syndrome with fewer side effects. Similarly, companies are also entering into strategic agreements with distributors and local players to increase the availability of their products in order to expand their market footprint.

After a detailed study of the U.S. polycystic ovarian syndrome treatment market, the analysts have found that the U.S. shows a high prevalence rate of polycystic ovarian syndrome. This syndrome is associated with several other conditions such as type 2 diabetes mellitus, obesity, hirsutism and others. Also, women with polycystic ovarian syndrome are at a greater risk of developing type 2 diabetes mellitus. According to the report, the U.S. polycystic ovarian syndrome treatment market comprises several pharmaceutical drugs manufacturers based in the U.S. However, due to lack of FDA approved drugs for PCOS treatment, the market is dominated by small generic drugs manufacturers. These companies follow strong marketing and distribution strategies for facilitating a higher adoption of their polycystic ovarian syndrome treatment drugs across the country.

Persistence Market Research provides key strategic recommendations for existing and new players in the market

The U.S. polycystic ovarian syndrome treatment market report begins with an overview of the entire market. The report also underlines factors influencing the growth of the U.S. polycystic ovarian syndrome treatment market along with a detailing of the key trends, drivers, restraints, opportunities for market players and regulations. Impact analysis of key growth drivers and restraints based on the weighted average model along with important trends is included in the report to better equip clients with information and hidden insights. At the end of the report, Persistence Market Research provides key strategic recommendations for both existing and new players in the market to emerge sustainably profitable. A detailed analysis has been provided for each market segment in terms of market size, Y-o-Y growth rate, absolute $ opportunity, market attractiveness index and BPS analysis.

The next few sections provide a detailed analysis of every segment and sub-segment of the U.S. polycystic ovarian syndrome treatment market. The report further highlights the growth trends of the polycystic ovarian syndrome treatment market across the U.S and presents a market outlook for 2016–2024 – showcasing key trends contributing to the growth of the polycystic ovarian syndrome treatment market in the U.S. as well as an analysis of the extent to which drivers are influencing this market. The final section of the report includes detailed company profiles with company-specific long-term and short-term strategies, key offerings, and recent developments in the U.S polycystic ovarian syndrome treatment market.

Market Segmentation

By Drug Class

Oral Contraceptives
Insulin Sensitizing Agents
Anti-Depressants
Ornithine
Decarboxylase Inhibitors
Aromatase Inhibitors and SERMs
Diuretics
By Distribution Channel

Hospital Pharmacies
Drug Stores / OTC
e-Commerce
Fertility Clinics
Research Methodology

The report considers 2015 as the base year and provides data for the forecast period 2016–2024. To deduce market size, the report considers various viewpoints based on extensive primary and secondary research. The report begins by sizing the current market – a key indicator of how the market is likely to grow during the forecast period. Given the characteristics of the market, the report presents triangulated data on the basis of supply side and demand side analysis and other dynamics of the U.S polycystic ovarian syndrome treatment market. Indicators such as the number of polycystic ovarian syndrome patients per year, diagnosis rate, treatment rate, etc., have been considered to arrive at the indicated market numbers. Similarly, historical trends pertaining to the demand for drugs among polycystic ovarian syndrome patients have been analyzed to track data. Yearly change in inflation rate has not been factored while forecasting market numbers. Bottom-up approach has been used to assess market numbers for each product category, while top-down approach has been used to counter-validate the reached numbers.

  • Table 1 : U.S. Polycystic Ovary Syndrome Drugs Market Value Analysis, by Drug Class, 2015�2024 (US$ Mn)
  • Table 2 : U.S. Polycystic Ovary Syndrome Drugs Value Analysis, by Distribution Channel, 2015�2024 (US$ Mn)
  • Figure 1 : U.S. Polycystic Ovary Syndrome Drugs Market Value Share By, Drug Class, 2016
  • Figure 2 : U.S. Polycystic Ovary Syndrome Drugs Market Value Share By, Distribution Channel, 2016
  • Figure 3 : U.S. Polycystic Ovary Syndrome Drugs Market Value, US$ Mn, 2015�2024
  • Figure 4 : U.S. Polycystic Ovary Syndrome Drugs Market Share Analysis, by Drug Class Type (%), 2016-2024
  • Figure 5 : U.S. Polycystic Ovary Syndrome Drugs Market Y-o-Y Growth (%), by Drug Class, 2016-2024
  • Figure 6 : U.S. Polycystic Ovary Syndrome Drugs Market Attractiveness Index, by Drug Class, 2016-2024
  • Figure 7 : U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Contraceptives, 2016 � 2024
  • Figure 8 : U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Contraceptives Segment, 2016 � 2024 (US$ Mn
  • Figure 9 : U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Insulin Sensitizing Agents, 2016 � 2024
  • Figure 10 : U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Insulin Sensitizing Agents Segment, 2016 � 2024 (US$ Mn)
  • Figure 11 : U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Anti-Depressants, 2016 � 2024
  • Figure 12 : U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Anti-Depressants Segment, 2016 � 2024 (US$ Mn)
  • Figure 13 : U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Ornithine Decarboxylase Inhibitors, 2016 � 2024
  • Figure 14 : U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Ornithine Decarboxylase Inhibitors Segment, 2016 � 2024 (US$ Mn)
  • Figure 15 : U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Aromatase Inhibitors & SERMs, 2016 � 2024
  • Figure 16 : U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Aromatase Inhibitors & SERMs Segment, 2016 � 2024 (US$ Mn)
  • Figure 17 : U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Diuretics, 2016 � 2024
  • Figure 18 : U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Diuretics Segment, 2016 � 2024 (US$ Mn)
  • Figure 19 : U.S. Polycystic Ovary Syndrome Drugs Market Share Analysis, by Distribution Channel (%), 2016 & 2024
  • Figure 20 : U.S. Polycystic Ovary Syndrome Drugs Market Y-o-Y Growth (%), by Distribution Channel, 2016-2024
  • Figure 21 : U.S. Polycystic Ovary Syndrome Drugs Market Attractiveness Index, by Distribution Channel, 2016-2024
  • Figure 22 : U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2016 � 2024
  • Figure 23 : U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Hospital Pharmacies, 2016 � 2024 (US$ Mn)
  • Figure 24 : U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Drug Stores/OTC, 2016 � 2024
  • Figure 25 : U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Drug Stores/OTC, 2016 � 2024 (US$ Mn)
  • Figure 26 : U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by E-commerce, 2016 � 2024
  • Figure 27 : U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by E-commerce, 2016 � 2024 (US$ Mn)
  • Figure 28 : U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Fertility Clinics, 2016 � 2024
  • Figure 29 : U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Fertility Clinics, 2016 � 2024 (US$ Mn)

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organization of all sizes.

Persistence Market Research
Price: $4900

Become a Member

Already a member? Login here.

Have a Question? Ask Us.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS